Evidence review: Open Peptide Project (verified against primary PubMed, ClinicalTrials.gov & FDA records) · Last checked 2026-10-27. ← Back to Evidence Library

503A vs. 503B compounding pharmacies vs. FDA-approved peptide drugs

Four very different legal and quality tiers that are often lumped together as "peptides"

Evidence verdict: Based on the FD&C Act, FDA rules and FDA web guidance. Legal status changes; check FDA's live lists for any specific substance. [3, 4, 1]

Last reviewed: Oct 27, 2026

In 30 seconds

• FDA-approved peptide drugs went through FDA review of safety, effectiveness and manufacturing quality. Most peptides (40 amino acids or fewer) are approved as drugs under the FD&C Act. Only chains longer than 40 amino acids count as "proteins" and are licensed as biologics under section 351 of the PHS Act. [1, 2] [Regulatory]
• 503A pharmacies compound for an identified individual patient on a valid prescription. They are overseen mainly by state boards of pharmacy and are not held to federal CGMP. [3, 4] [Regulatory]
• 503B outsourcing facilities register with FDA, must follow CGMP, are inspected on a risk-based schedule and must report adverse events. Their products are still not FDA-approved. [5, 4] [Regulatory]
• "Research use only" vials are none of the above. They have no FDA review for human use, no prescription and no compounding-law protections. [4, 6] [Regulatory]

Tier 1: FDA-approved peptide drugs

Approved peptide drugs carry a full prescribing label and are made to FDA-reviewed specifications. Which law applies depends on size. FDA's 2020 final rule defines a "protein" as an alpha-amino-acid polymer with a specific defined sequence of more than 40 amino acids. Proteins are biological products licensed under PHS Act section 351. Peptides of 40 amino acids or fewer stay drugs under the FD&C Act, approved through new drug applications. [1, 2] [Regulatory] On March 23, 2020, approved drug applications for products that met the protein definition were "deemed to be" biologics licenses. [2] That is why semaglutide (Wegovy, NDA 215256) and tirzepatide (Zepbound, NDA 217806) are NDAs, while tesamorelin (Egrifta SV, 44 amino acids) and somatropin (Genotropin) now carry BLA numbers. [7, 8, 9, 10] [Regulatory]

Tier 2: 503A compounding pharmacies

Section 503A exempts a compounded drug from FDA approval, from some labeling rules and from CGMP only if, among other conditions, it is compounded for an identified individual patient based on a valid prescription. [3] [Regulatory] FDA says drugs compounded by a licensed pharmacist under 503A are not subject to CGMP, and that state boards of pharmacy generally have primary day-to-day oversight of these pharmacies. [4] [Regulatory] A 503A pharmacy may use a bulk substance only if it meets the law's criteria, such as a USP monograph, a component of an approved drug, or a place on FDA's 503A bulks list. [3, 11] [Regulatory]

Tier 3: 503B outsourcing facilities

The Drug Quality and Security Act of 2013 created section 503B. An outsourcing facility compounds sterile drugs at one address, registers with FDA, and must comply with CGMP. FDA inspects it on a risk-based schedule, and it must report adverse events and tell FDA what it makes. [5] [Regulatory] FDA is explicit that compounded drugs, including 503B products, are not FDA-approved: FDA does not verify their safety, effectiveness or quality before they are marketed. [4] [Regulatory]

Where many popular peptides sit

FDA lists several peptides, including BPC-157, thymosin alpha-1 and ipamorelin, among bulk substances that may present significant safety risks in compounding. It cites concerns such as immunogenicity and peptide-related impurities. [6] [Regulatory] A 2026 review summarizes the Pharmacy Compounding Advisory Committee's peptide recommendations and what they mean for compounders. [12] [Review] Status is substance-by-substance and changes, so check the live FDA lists; this page does not say any specific peptide may be compounded.

Tier 4: "research use only" products

Products labeled "research use only" or "not for human consumption" are not approved drugs, not 503A prescriptions and not 503B products. None of the tiers above covers them. FDA advises consumers to check any online pharmacy or telehealth service before using it. [4] [Regulatory] Market testing has repeatedly found such products mislabeled or contaminated. [13, 14] [Observational] See the research-use-only guide for more.

Quick comparison

	FDA-approved drug	503A pharmacy	503B outsourcing facility	Research-use-only vial
FDA premarket review	Yes	No	No	No
Prescription required	Yes (Rx drugs)	Yes, for an identified patient	Varies; Caution not detailed here	No
Federal CGMP	Yes	No	Yes	No
Main inspector	FDA	State board of pharmacy	FDA (risk-based)	None

Sources: [3, 4, 5]. UNVERIFIED cells mark points the cited FDA pages do not state.

Evidence levels used on this page

• [Regulatory] FDA, USP or WADA primary document or an FDA-approved label. [Controlled study] randomized trial or systematic review of trials. [Observational] surveillance, pharmacovigilance or cohort data. [Lab] analytical, cell or animal work. [Guidance] professional-society guidance. [Policy] Open Peptide Project published policy.

Related

Research-use-only peptides and FDA 503A/503B law, Counterfeit and mislabeled gray-market peptides, Tesamorelin, Semaglutide

References

1. US FDA. Final rule: Definition of the term "biological product". Federal Register 85 FR 10057, Feb 21, 2020 (effective Mar 23, 2020). https://www.federalregister.gov/documents/2020/02/21/2020-03505/definition-of-the-term-biological-product
2. US FDA. The "Deemed to be a License" provision of the BPCI Act: questions and answers, guidance for industry. https://www.fda.gov/media/135838/download
3. Federal Food, Drug, and Cosmetic Act section 503A, 21 U.S.C. 353a (pharmacy compounding). https://www.law.cornell.edu/uscode/text/21/353a
4. US FDA. Compounding and the FDA: questions and answers (content current as of 09/16/2025). https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
5. US FDA. Information for outsourcing facilities (content current as of 03/29/2022). https://www.fda.gov/drugs/human-drug-compounding/information-outsourcing-facilities
6. US FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of 04/22/2026). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
7. WEGOVY (semaglutide) injection and tablets, prescribing information, Novo Nordisk (NDA 215256). DailyMed setid ee06186f-2aa3-4990-a760-757579d8f77b, published Jun 30, 2026.
8. ZEPBOUND (tirzepatide) prescribing information, Eli Lilly (NDA 217806). DailyMed/openFDA setid 487cd7e7-434c-4925-99fa-aa80b1cc776b, effective Aug 28, 2026.
9. EGRIFTA SV (tesamorelin) prescribing information, Theratechnologies (BLA 022505). setid 3d783378-b02d-4f19-99dd-0fc91a042224, effective Jul 29, 2026.
10. GENOTROPIN (somatropin) prescribing information, Pfizer (BLA 020280). setid ffebf88b-d257-4542-9808-74d9b7167765, effective Aug 4, 2026.
11. US FDA. Bulk drug substances used in compounding (503A and 503B lists). https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding
12. Willis et al. Synthetic peptides in pharmacy compounding: analysis of PCAC recommendations and industry safety standards. Int J Pharm Compd. 2026. PMID 42752426.
13. Ashraf AR, et al. Multifactor quality and safety analysis of semaglutide products sold by online sellers without a prescription. J Med Internet Res. 2024. PMID 39509151.
14. Van Wagoner RM, et al. Chemical composition and labeling of substances marketed as selective androgen receptor modulators and sold via the internet. JAMA. 2017. PMID 29183075.

Disclaimer: This page is for education only. It is not medical advice, and it does not endorse using, buying or preparing any unapproved product. Talk to a licensed clinician before you start, stop or change any treatment.